A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).

被引：1
|
作者：
Attard, Gerhardt
Merseburger, Axel S.
Sternberg, Cora N.
Cerbone, Linda
Recine, Federica
Jones, Robert J.
Feyerabend, Susan
Berruti, Alfredo
Joniau, Steven
Schatteman, Peter
Geczi, Lajos
Tenke, Peter
Werbrouck, Patrick
Lefresne, Florence
Shelby, Florence Nave
Lahaye, Marjolein
Pick, Corinna
Tombal, Bertrand F.
机构：
[1] Inst Canc Res, London SW3 6JB, England
[2] Royal Marsden Hosp, London SW3 6JJ, England
[3] Med Univ Lubeck, Dept Urol, D-23538 Lubeck, Germany
[4] San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy
[5] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[6] Studienpraxis Urol, Nurtingen, Germany
[7] Univ Brescia, Med Oncol, Spedali Civili Hosp, Brescia, Italy
[8] Univ Hosp Leuven, Leuven, Belgium
[9] Onze Lieve Vrouw Hosp, Aalst, Belgium
[10] Natl Inst Oncol, Chemotherapy & Clin Pharmacol Dept C, Budapest, Hungary
[11] Jahn Ferenc Del Pesti Korhaz, Dept Urol, Budapest, Hungary
[12] AZ Groeninge, Kortrijk, Belgium
[13] Janssen Cilag, Paris, France
[14] Janssen Cilag, Tilburg, Netherlands
[15] Janssen Cilag, Neuss, Germany
[16] Catholic Univ Louvain, Inst Rech Expt & Clin, B-1200 Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期
关键词：
D O I：
10.1200/jco.2016.34.2_suppl.261
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
261
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Nanus, David M.
    Posadas, Edwin M.
    Petrylak, Daniel Peter
    Bruce, Justine Yang
    Lim, Emerson A.
    Peng, Weimin
    Maul, Raymond Scott
    Gonzalez, Martha
    Tran, Namphuong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Posadas, Edwin M.
    Bruce, Justine Yang
    Lim, Emerson A.
    Petrylak, Daniel Peter
    Peng, Weimin
    Maul, Raymond Scott
    Smit, Hans W.
    Tran, Namphuong
    Nanus, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.
    Clarke, Noel
    Wiechno, Pawel J.
    Alekseev, Boris
    Sala, Nuria
    Jones, Robert
    Kocak, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Assessment of prognostic factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) after docetaxel (DOC).
    Cavaliere, Carla
    Caffo, Orazio
    Ortega, Cinzia
    D'aniello, Carmine
    Di Napoli, Marilena
    Cecere, Sabrina Chiara
    Della Pepa, Chiara
    Crispo, Anna
    Maines, Francesca
    Ruatta, Fiorella
    Iovane, Gelsomina
    Montella, Maurizio
    Pignata, Sandro
    Facchini, Gaetano
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Randomized phase II trial of abiraterone ± dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Quinn, David I.
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan G.
    Kuhn, Peter
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald F.
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    De Boer, Carla
    Todd, Mary Beth
    Yu, Margaret K.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Impact of prior response to abiraterone acetate (AA) on subsequent activity of docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Azad, Arun
    Lester, Renee
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [8] ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (AA)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Bandekar, Rajesh
    Maneval, Edna Chow
    de Boer, Carla
    Todd, Mary
    Yu, Margaret K.
    Scher, Howard I.
    CANCER RESEARCH, 2014, 74 (19)
  • [9] Population-based analysis of a novel prognostic model for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA).
    Azad, Arun
    Lester, Renee
    Leibowitz-Amit, Raya
    Joshua, Anthony M.
    Heng, Daniel Yick Chin
    Eigl, Bernhard J.
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Efficacy and safety of abiraterone acetate (AA) in elderly (75 years) chemo-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Smith, M. R.
    Rathkopf, D.
    Mulders, P.
    Carles, J.
    Van Poppel, H.
    Li, J.
    Kheoh, T.
    Griffin, T.
    Molina, A.
    Ryan, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S708 - S708
12345